China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
This article was originally published in The Gray Sheet
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.
You may also be interested in...
China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11
The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.
Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.